| アブストラクト | PURPOSE: We aimed to develop a standardized method to calculate daily dose (i.e., the amount of drug a patient was exposed to per day) of any drug on a global scale using only drug information of typical observational data in the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) and a single reference table from Observational Health Data Sciences And Informatics (OHDSI). MATERIALS AND METHODS: The OMOP DRUG_STRENGTH reference table contains information on the strength or concentration of drugs, whereas the OMOP DRUG_EXPOSURE table contains information on patients' drug prescriptions or dispensations/claims. Based on DRUG_EXPOSURE data from the primary care databases Clinical Practice Research Datalink GOLD (United Kingdom) and Integrated Primary Care Information (IPCI, The Netherlands) and healthcare claims from PharMetrics(R) Plus for Academics (USA), we developed four formulas to calculate daily dose given different DRUG_STRENGTH reference table information. We tested the dose formulas by comparing the calculated median daily dose to the World Health Organization (WHO) Defined Daily Dose (DDD) for six different ingredients in those three databases and additional four international databases representing a variety of healthcare settings: MAITT (Estonia, healthcare claims and discharge summaries), IQVIA Disease Analyzer Germany (outpatient data), IQVIA Longitudinal Patient Database Belgium (outpatient data), and IMASIS Parc Salut (Spain, hospital data). Finally, in each database, we assessed the proportion of drug records for which daily dose calculations were possible using the suggested formulas. RESULTS: Applying the dose formulas, we obtained median daily doses that generally matched the WHO DDD definitions. Our dose formulas were applicable to >85% of drug records in all but one of the assessed databases. CONCLUSION: We have established and implemented a standardized daily dose calculation in OMOP CDM providing reliable and reproducible results. |
|---|
| ジャーナル名 | Pharmacoepidemiology and drug safety |
|---|
| Pubmed追加日 | 2024/5/22 |
|---|
| 投稿者 | Burkard, Theresa; Lopez-Guell, Kim; Gorbachev, Artem; Bellas, Lucia; Jodicke, Annika M; Burn, Edward; de Ridder, Maria; Mosseveld, Mees; Gratton, Jasmine; Seager, Sarah; Vojinovic, Dina; Mayer, Miguel Angel; Ramirez-Anguita, Juan Manuel; Machin, Angela Leis; Oja, Marek; Kolde, Raivo; Bonadt, Klaus; Prieto-Alhambra, Daniel; Reich, Chistian; Catala, Marti |
|---|
| 組織名 | Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences;(NDORMS), University of Oxford, Oxford, UK.;Odysseus Data Services, Cambridge, Massachusetts, USA.;Clinical Pharmacology Service, Hospital Universitari Vall d'Hebron, Barcelona,;Spain.;Department of Medical Informatics, Erasmus University Medical Center, Rotterdam,;The Netherlands.;IQVIA Ltd, London, UK.;IQVIA Solutions B.V, Amsterdam, the Netherlands.;Management and Control Department, Hospital del Mar Barcelona, Barcelona, Spain.;Research Program on Biomedical Informatics (GRIB). Hospital del Mar Research;Institute (IMIM), Barcelona, Spain.;Universitat Pompeu Fabra, Barcelona, Spain.;Institute of Computer Science, University of Tartu, Tartu, Estonia.;IQVIA Commercial GmbH & Co. OHG, Frankfurt, Germany. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38773798/ |
|---|
